Nasdaq ikna.

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Nasdaq ikna. Things To Know About Nasdaq ikna.

Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com. BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR ...Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.Nov 24, 2023 · Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.

The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation ...Check Out Our Latest Research Report on IKNA. Ikena Oncology Stock Up 9.8 %. Shares of NASDAQ IKNA opened at $1.46 on Monday. Ikena Oncology has a twelve month low of $1.02 and a twelve month high ...

Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksFranchiser Inter IKEA said sales of products and services at all IKEA stores and online totalled 41.9 billion euros ($48.7 billion) - up 6% from the previous fiscal year and up 1% from pre ...BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, ... The Invesco QQQ Trust offers a way to play tech strength by matching the Nasdaq 100 index.IKNA Edit my quotes Ikena Oncology, Inc. Common Stock (IKNA) Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Pre-Market Charts NEWS & …BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Mar 7, 2022 · BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it ...

23 mai 2023 ... Dolar, Borsa, Altın, Eurobond, Bankalar ve Nasdaq Hakkında ... İlahiyatçı Kızlar Celal Şengör'ü "Bir Yaratan" Olduğuna İkna Etmeye Çalışıyorlar.BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, and the Vall d’Hebron ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...10 août 2023 ... (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Nov 9, 2023 · Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has gone decline by -62.23 in comparison to its previous close of 4.13, however, the company has experienced a -61.58% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology,

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Oct 26, 2022 · BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Nasdaq Short Interest Days Nasdaq Short Interest Days NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- At the end of the settlement date of November 15, 2023, short interest in 3,169 Nasdaq Global ...IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Aug 7, 2023 · Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ... BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Nov 18, 2023 · Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value. Formula One Group (NASDAQ:FWONA) has seen a decrease in hedge fund sentiment lately. Formula One Group (NASDAQ: FWONA ) was in 19 hedge funds' portfolios at the end of the first quarter of 2021 ...In September 2022, Ikena Oncology had US$174m in cash, and was debt-free. Importantly, its cash burn was US$72m over the trailing twelve months. Therefore, from September 2022 it had 2.4 years of ...The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61.IKNA Price $1.40 Fair Value Price N/A Market Cap $67.56M 52 Week Low $1.02 52 Week High $7.64 P/E -0.86x P/B 0.43x P/S 13.48x PEG N/A Dividend Yield N/A …

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...

Financial Results for the Year Ended December 31, 2022. As of December 31, 2022, Ikena had $156.9 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient ...

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Oct 1, 2021 · BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ... 9 nov. 2023 ... Ikena Oncology, Inc (NASDAQ: IKNA) reported its quarterly financial results and presented preliminary data from the ongoing dose escalation ...BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...

Gainers Celcuity Inc. (NASDAQ:CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreemen...Nov 18, 2023 · Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value. May 18, 2023 · IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ... 17 déc. 2021 ... ... (NASDAQ: ADGI), Icosavax (NASDAQ: ICVX), Imago BioSciences (NASDAQ: IMGO), Ikena Oncology (NASDAQ: IKNA), Nuvation Bio (NYSE: NUVB), Sana ...Instagram:https://instagram. biolife stocktop options trading platformsqqq price targettrading options td ameritrade Oct 1, 2021 · BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ... does robinhood allow futures tradingfirst republick bank stock Oct 1, 2021 · BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ... what's a gold bar worth Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...15 mai 2023 ... (NASDAQ: IKNA) (“Ikena” or the “Company”) is a targeted oncology company, focused on developing differentiated therapies for patients in ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...